Van Eygen V - Search Results

1

Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications.

Vandenbroucke I, Van Marck H, Verhasselt P, Thys K, Mostmans W, Dumont S, Van Eygen V, Coen K, Tuefferd M, Aerssens J. Vandenbroucke I, et al. Among authors: van eygen v, van marck h. Biotechniques. 2011 Sep;51(3):167-77. doi: 10.2144/000113733. Biotechniques. 2011. PMID: 21906038 Free article.

2

HIV-1 nucleotide mixture detection in the virco(®)TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing.

De Wolf H, Van Marck H, Mostmans W, Thys K, Vandenbroucke I, Van Eygen V, Pattery T, Verhasselt P, Aerssens J. De Wolf H, et al. Among authors: van eygen v, van marck h. J Virol Methods. 2011 Jul;175(1):129-32. doi: 10.1016/j.jviromet.2011.04.023. Epub 2011 Apr 27. J Virol Methods. 2011. PMID: 21549149

3

Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.

Van Eygen V, Thys K, Van Hove C, Rimsky LT, De Meyer S, Aerssens J, Picchio G, Vingerhoets J. Van Eygen V, et al. Among authors: van hove c. J Med Virol. 2016 May;88(5):798-806. doi: 10.1002/jmv.24395. Epub 2015 Oct 5. J Med Virol. 2016. PMID: 26412111

4

HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays.

Vandenbroucke I, Van Marck H, Mostmans W, Van Eygen V, Rondelez E, Thys K, Van Baelen K, Fransen K, Vaira D, Kabeya K, De Wit S, Florence E, Moutschen M, Vandekerckhove L, Verhofstede C, Stuyver LJ. Vandenbroucke I, et al. Among authors: van eygen v, van baelen k, van marck h. AIDS Res Ther. 2010 Feb 15;7:4. doi: 10.1186/1742-6405-7-4. AIDS Res Ther. 2010. PMID: 20804564 Free PMC article.

5

Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients.

Messiaen P, Verhofstede C, Vandenbroucke I, Dinakis S, Van Eygen V, Thys K, Winters B, Aerssens J, Vogelaers D, Stuyver LJ, Vandekerckhove L. Messiaen P, et al. Among authors: van eygen v. Virology. 2012 Apr 25;426(1):7-11. doi: 10.1016/j.virol.2012.01.002. Epub 2012 Feb 4. Virology. 2012. PMID: 22305619 Free article.

6

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin.

Fevery B, Thys K, Van Eygen V, Verbinnen T, Van Rossem E, Buelens A, Aerssens J, Witek J, Picchio G, De Meyer S, Lenz O. Fevery B, et al. Among authors: van eygen v, van rossem e. Open Forum Infect Dis. 2016 Mar 14;3(2):ofw052. doi: 10.1093/ofid/ofw052. eCollection 2016 Mar. Open Forum Infect Dis. 2016. PMID: 27186579 Free PMC article.

7

HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays.

Van Baelen K, Vandenbroucke I, Rondelez E, Van Eygen V, Vermeiren H, Stuyver LJ. Van Baelen K, et al. Among authors: van eygen v. J Virol Methods. 2007 Dec;146(1-2):61-73. doi: 10.1016/j.jviromet.2007.06.003. Epub 2007 Jul 19. J Virol Methods. 2007. PMID: 17640743

8

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ. Vandekerckhove L, et al. Among authors: van eygen v, van baelen k, van marck h. J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31. J Antimicrob Chemother. 2011. PMID: 21196489 Free PMC article.

9

Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.

Picchio GR, Rimsky LT, Van Eygen V, Haddad M, Napolitano LA, Vingerhoets J. Picchio GR, et al. Among authors: van eygen v. Antivir Ther. 2014;19(8):819-23. doi: 10.3851/IMP2771. Epub 2014 Apr 4. Antivir Ther. 2014. PMID: 24704709

10

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.

Jeffrey JL, St Clair M, Wang P, Wang C, Li Z, Beloor J, Talarico C, Fridell R, Krystal M, White CT, Griffith S, D'Amico R, Smith K, Van Eygen V, Vingerhoets J, Vandermeulen K, Spreen W, van Lunzen J. Jeffrey JL, et al. Among authors: van eygen v. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0170221. doi: 10.1128/AAC.01702-21. Epub 2022 Jan 3. Antimicrob Agents Chemother. 2022. PMID: 34978890 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters